Consensus Cloud Solutions Q2 FY26 earnings call CCSI

Consensus formed a new Healthcare Strategy and Solutions group, led by Steve Tolle as Chief Healthcare Solutions Officer, to own the non-fax healthcare product portfolio, go-to-market efforts, and strategy. This group aims to build on the existing eFax foundation by transforming unstructured fax data into structured data for EHR integration and clinical workflow. The company expects meaningful contributions from this group to its non-fax revenue in 2028 and beyond, with continued hiring into the business unit through 2027.

The company completed a tuck-in acquisition of doc.health, a workflow platform developed by a practicing medical professional. This platform handles clinically adjacent work such as referral management, care coordination, and patient follow-up, fitting perfectly into Consensus's Harmony platform vision. The acquisition brings 14 employees, a customer base, pipeline, and key technologies. Its financial impact for FY26 is incorporated into guidance, contributing approximately $1 million in revenue, a negative $0.6 million to EBITDA, and a negative $0.02 to EPS.

The Department of Veterans Affairs (VA) issued a policy mandating ECFax, powered by eFax, as its secure fax solution. This mandate is driving a highly qualified lead pipeline across the public sector and adjacent organizations like government contractors. The VA rollout is estimated to be 65-80% complete. Management is highly confident the VA revenue contribution will be north of $9 million in 2026, serving as a powerful door opener for further public sector wins, though other large agency wins are expected to take time.

The SoHo channel is being managed strictly for cash optimization and contribution margin, rather than absolute subscriber volume or ARPA. This disciplined, yield-first approach is expected to result in volatility in net adds, ARPA, and total revenue in the coming months^⏳. While the year-over-year decline narrowed to 4.7% in Q2 FY26 (from 9.5% in Q1), management views this specific level of improvement as exceptional and not necessarily recurring at the same rate in future periods, expecting a 5-7% decline in Q3 and Q4.

Consensus continues to view its stock as attractive, with a free cash flow yield of 16-17%. The Board of Directors authorized an increase in the equity repurchase plan to $200 million, with $118 million remaining. In Q2 FY26, the company repurchased 300,000 shares for approximately $9.6 million. Management also noted the 6.5% high-yield notes become callable at 101.625% in October 2026, and at par in October 2027, but sees limited volume for open market purchases. The company may also pay down its revolver with U.S. cash due to a 2-2.5% interest arbitrage.

After slower hiring in Q1, the company caught up in Q2, increasing its employee count to approximately 550, up 32 since the beginning of the year, partly due to the doc.health acquisition. This growth in headcount, primarily in go-to-market, product, and healthcare solutions, will lead to increased compensation expenses in H2 FY26. Additionally, accounting and professional fees for the year-end audit, expensed as incurred, will add approximately $1.3 million in costs in both Q3 and Q4, contributing to lower expected EBITDA margins in the second half of the year compared to H1.

Consensus booked a non-cash GAAP gain of $5.3 million on an investment in an AI partner company during Q2 FY26. This gain was triggered by a priced funding round for the AI company, which is one of the third parties used in conjunction with Consensus's Clarity product. The company's $10.5 million cash investment in the business is now valued at approximately $16 million. Management noted that such investments are inherently risky and subject to future valuation changes.